Edit Content


VTI Ebook cover

New E-Publication on Presbyopia Available for Download

January 11, 2024 Visioneering Technologies Inc. (VTI) and Jobson Publishing have collaborated on a new 14-page e-publication, Redefine What’s Possible, which features articles about the growing presbyopia population and the innovative solutions that NaturalVue Enhanced


Lumenis Introduces OptiPLUS Radio Frequency Device for Dry Eye Disease

November 10, 2023 YOKNE’AM ILLIT, Israel,  — Lumenis has announced the launch of OptiPLUS, the first dual frequency radiofrequency (RF) device on the market. It delivers heat across different tissue layers, increasing blood circulation to promote medical performance and aesthetic results.1 OptiPLUS is a complementary device to Lumenis’ novel OptiLIGHT technology, which targets


Eyenovia Announces FDA Approval of Coastline as Mydcombi Manufacturer

November 3, 2023 NEW YORK — Eyenovia, Inc., announced that the FDA has approved Eyenovia’s Supplemental New Drug Application (sNDA), adding Coastline International as a contract manufacturer. Coastline will manufacture cartridge subassemblies for Mydcombi, the only FDA-approved


The FDA Approves Qlosi for the Treatment of Presbyopia

October 19, 2023 PONTE VEDRA, Fla. — Orasis Pharmaceuticals has announced that the U.S. Food and Drug Administration (FDA) has approved Qlosi (pilocarpine hydrochloride ophthalmic solution) 0.4% for the treatment of presbyopia in adults. Qlosi is

Lumify Eye Illuminations

Bausch + Lomb Launches Lumify Eye Illuminations in the U.S.

October 13, 2023 VAUGHAN, Ontario —  Bausch + Lomb Corporation has announced the U.S. launch of Lumify Eye Illuminations, a new line of hypoallergenic specialty eye care products scientifically developed to cleanse, nourish and brighten the sensitive eye


Izervay Approved for the Treatment of Geographic Atrophy

August 8, 2023 TOKYO — Astellas Pharma Inc. announced the U.S. Food and Drug Administration (FDA) approved Izervay (avacincaptad pegol intravitreal solution) for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD).


FDA Approves XDEMVY for the Treatment of Demodex Blepharitis

July 25, 2023 IRVINE, Calif.  ­— Tarsus Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) approved XDEMVY (lotilaner ophthalmic solution) 0.25% for the treatment of demodex blepharitis. XDEMVY, formerly known as TP-03,

A bottle of TobraDex

Harrow Acquires Santen’s Branded Ophthalmic Portfolio

July 18, 2023   NASHVILLE, Tenn. — Harrow Health, Inc. has announced agreements with affiliates of Santen Pharmaceutical Co., Ltd., under which Harrow will acquire certain U.S. and Canadian commercial rights for the following branded

BVI ribbon cutting

BVI Expands IOL Capacity with New Facility in Belgium

July 19, 2023 LIÈGE, Belgium – BVI Medical Inc. has opened a new facility here to increase its intraocular lens (IOL) production capacity. This results in a sizeable increase in BVI’s IOL production capacity, unlocking

RVL Launches ELEVATE Prescription E-commerce Platform

July 6, 2023 BRIDGEWATER, N.J. – RVL Pharmaceuticals has launched ELEVATE, a first-of-its-kind, proprietary prescription e-commerce platform. This platform aligns with RVL’s vision of seamlessly integrating its products into customers’ practices while further enhancing patient

VEVYE eye drops

FDA Approves VEVYE for the Treatment of Dry Eye Disease

June 8, 2023 HEIDELBERG, Germany and CAMBRIDGE, Mass.— Novaliq GmbH, has announced that the U.S. Food and Drug Administration (FDA) has approved VEVYE (cyclosporine ophthalmic solution) 0.1% for the treatment of the signs and symptoms of

Glaukos Announces FDA Acceptance of NDA Submission for iDose TR

May 5, 2023 Aliso Viejo, Calif. – Glaukos Corporation announced it has received the “Day 74” notification from the U.S. Food and Drug Administration acknowledging the previously submitted New Drug Application (NDA) for iDose TR (travoprost intraocular

The ZEISS Cataract Suite with ZEISS CALLISTO® eye for computer assisted cataract surgery

FDA Approves ZEISS CT LUCIA 621P Monofocal IOL

April 25, 2023 JENA, Germany, and DUBLIN, Calif. – The U.S. Food and Drug Administration (FDA) has approved the CT LUCIA 621P Monofocal IOL from ZEISS Medical Technology. The aspheric, monofocal, single-piece C-loop IOL features the patented

FDA Approves SYFOVRE as First and Only Treatment for Geographic Atrophy

FDA Approves SYFOVRE for Geographic Atrophy

April 11, 2023 WALTHAM, Mass. — The U.S. Food and Drug Administration has approved SYFOVRE (pegcetacoplan injection) for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD). From global biopharmaceutical company Apellis

FDA Approves Twice-Daily Dosing of Vuity

FDA Approves Twice-Daily Dosing  of Vuity

April 11, 2023 NORTH CHICAGO, Ill. – AbbVie, the parent company of Allergan, has announced that the FDA has approved a twice-daily dosing option of Vuity (pilocarpine HCl ophthalmic solution) 1.25% in adults with presbyopia.

Scroll to Top